Gilead’s COVID-19 drug remdesivir: the transfer pricing implications

Article by Dr. J. Harold McClure (first published on MNE Tax)

Gilead Sciences today announced its pricing plan for its COVID-19 therapy, remdesivir, in preparation for it to begin charging for the drug in July. The announcement comes as a bit of a surprise, as many analysts predicted that prices for developed nations would be set higher.

Remdesivir may prove to be an important therapy for COVID-19 and thus extremely profitable to Gilead.

An interesting issue for transfer pricing practitioners is where Gilead’s potentially massive profits from remdesivir will be taxed.

Continue reading at MNE Tax.

Related Articles